您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
PRO / Antibodies

Anti-Human VEGFR-2 (Ramucirumab Biosimilar)

Anti-Human VEGFR-2 (Ramucirumab Biosimilar)

英诺赛图(InnoCyto)的 Anti-Human VEGFR-2 (Ramucirumab Biosimilar)(克隆 Ramucirumab) 为人源 IgG1 抗体,靶向 VEGFR2(别名 VEGF-R2 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,288 起,仅供科研使用(RUO)。

生物试剂 供应商 上海英诺赛图 ↗ 型号 505001 更新 2026-11-12
参考价格区间
¥1,288
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 Anti-Human VEGFR-2 (Ramucirumab Biosimilar)(克隆 Ramucirumab) 为人源 IgG1 抗体,靶向 VEGFR2(别名 VEGF-R2 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,288 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

505001 | 1 mg | ¥1,288

505002 | 5 mg | ¥4,000

505003 | 20 mg | ¥9,424

Product Details

Product Description|Anti-Human VEGFR-2 (Ramucirumab Biosimilar)

Regulatory Status|RUO

Species specificity|Human

Storage Conditions|4ºC

Maximal Shelf Life|12 months

See All Formats|Clone Ramucirumab

Background Information

Ramucirumab is a fully human monoclonal antibody that belongs to the immunoglobulin G1 (IgG1) subclass and is engineered to bind with high specificity to vascular endothelial growth factor receptor 2 (VEGFR-2), also known as kinase insert domain receptor (KDR). Structurally, Ramucirumab is a glycoprotein with an approximate molecular weight of 147 kilodaltons (kDa). The molecule consists of two identical heavy chains and two identical light chains interconnected by disulfide bonds, forming the canonical Y-shaped antibody configuration typical of IgG molecules. It is produced using recombinant DNA technology in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells to ensure proper folding, disulfide linkage formation, and glycosylation compatible with human proteins.

The variable regions (VH and VL) of Ramucirumab define its antigen-binding site, composed of complementarity-determining regions (CDRs) that mediate specific, high-affinity recognition of the extracellular domain of VEGFR-2. This region corresponds to the receptor’s ligand-binding site for vascular endothelial growth factor A (VEGF-A), VEGF-C, and VEGF-D. By binding to this epitope, Ramucirumab sterically blocks the interaction between VEGFR-2 and its ligands, preventing receptor dimerization and autophosphorylation events required for downstream signaling activation. This inhibition disrupts intracellular pathways, primarily the MAPK (mitogen-activated protein kinase) and PI3K-AKT cascades, that regulate endothelial cell proliferation, migration, and survival in experimental systems investigating angiogenic control.

The Fc (fragment crystallizable) region of Ramucirumab is derived from human IgG1, providing structural stability and an extended half-life through neonatal Fc receptor (FcRn)–mediated recycling. It also permits limited engagement with Fc gamma receptors (FcγRs), enabling potential antibody-dependent cellular cytotoxicity (ADCC) under certain conditions, though this is not the primary mechanism. Overall, Ramucirumab exemplifies rational antibody design, combining precise receptor targeting, stable IgG architecture, and defined signaling blockade, to model ligand–receptor regulation and angiogenic signaling mechanisms at the molecular level.

Data Sheets

Cat # Size Price Quantity 5050011 mg Add to Cart5050025 mg Add to Cart50500320 mg Add to Cart

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格1 mg
CloneRamucirumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human VEGFR-2 (Ramucirumab Biosimilar)
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman VEGFR2
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
RRIDAB_3739326
Target NameVEGFR2, VEGF-R2, KDR, Tyrosin kinase growth factor receptor, homolog of FLK1 (FLK1), VEGFR
Antibody TypeRecombinant
目录价¥1,288

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). Anti-Human VEGFR-2 (Ramucirumab Biosimilar)(505001)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-vegfr-2-ramucirumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human VEGFR-2 (Ramucirumab Biosimilar)(505001). 产品目录. https://www.suprotek.cn/products/item/anti-human-vegfr-2-ramucirumab-biosimilar.html
@misc{biocsp_item_anti_human_vegfr_2_ramucirumab_biosimilar,
  title        = {Anti-Human VEGFR-2 (Ramucirumab Biosimilar)(505001)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/anti-human-vegfr-2-ramucirumab-biosimilar.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

Anti-Human VEGFR-2 (Ramucirumab Biosimilar)

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。